Market Cap 246.56M
Revenue (ttm) 22.60M
Net Income (ttm) -86.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -383.27%
Debt to Equity Ratio 0.00
Volume 127,400
Avg Vol 201,632
Day's Range N/A - N/A
Shares Out 56.55M
Stochastic %K 96%
Beta 3.02
Analysts Strong Sell
Price Target $11.71

Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cel...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 586 3100
Address:
500 Technology Square, Suite 700, Cambridge, United States
JarvisFlow
JarvisFlow Nov. 7 at 4:29 PM
Guggenheim updates rating for Foghorn Therapeutics ( $FHTX ) to Buy, target set at 12.
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 7 at 1:59 PM
+Initiations 11/7: $AARD $CNOB $FHTX $IMUX . -Initiations 11/7:
0 · Reply
LabPsycho
LabPsycho Nov. 5 at 5:42 PM
$FHTX Smarca2 as their lead...hmmm......look at PRLD and their smarca2 that they just seemingly tossed yesterday...
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 5 at 12:21 PM
$FHTX Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 4 at 2:26 PM
$FHTX fyi... prelude deprioritized their smarca2 program. this may have read through to foghorn's program. i think there other preclinical programs seem interesting and assume the lilly partnership could be maintained, if they also decide to deprioritize their smarca2 and pivot to another program. with that said, if they also announce a deprioritization, expect the stock price to drop. could be a good time to buy, at that time. wait for q3 er. “Having actively pursued the clinical development of our SMARCA2 selective degraders, we determined that complex biology and aggressiveness of disease in patients with SMARCA4 deletions will likely require early intervention and combination strategies to make a meaningful impact for patients." Prelude CEO
1 · Reply
LabPsycho
LabPsycho Nov. 4 at 2:23 PM
$FHTX @Baerchen 'partner with any Chinese or PD-L1 company....get any results you want [if the price is right!) Lol
0 · Reply
PaulLaurent
PaulLaurent Nov. 1 at 7:34 PM
🧭 Weekly Swing Recap $FHTX – Exceeded the target zone by $0.22. Clean execution; trims into strength worked. $IPHA – Target zone hit, but you had to be fast. Always place sells in the target zone—don’t wait for a unicorn (500%+). $NRGV – +14% from the entry; target not reached but still a profitable push. $NLSP$NCEL – +70% from the entry. Merger volatility knocked it after—lock gains when you have them. $ZENA – Never reached the entry zone—no entry. Tone: Discipline wins. Pre-set brackets, favor VWAP/pivot reclaims, scale out into strength, and protect gains if momentum cools.
3 · Reply
outlawinvestor1
outlawinvestor1 Oct. 28 at 4:35 PM
$FHTX great time to come into foghorn. tpd landscape is growing! only a matter of time before lilly buys this one. $GLUE $CCCC $ARVN $PRLD
0 · Reply
NotBornYesterday
NotBornYesterday Oct. 17 at 5:09 PM
$FHTX maybe…just maybe.
0 · Reply
stick_to_stocks
stick_to_stocks Oct. 7 at 8:58 PM
$FHTX added a bit
0 · Reply
Latest News on FHTX
Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Aug 16, 2023, 5:08 PM EDT - 2 years ago

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds


JarvisFlow
JarvisFlow Nov. 7 at 4:29 PM
Guggenheim updates rating for Foghorn Therapeutics ( $FHTX ) to Buy, target set at 12.
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 7 at 1:59 PM
+Initiations 11/7: $AARD $CNOB $FHTX $IMUX . -Initiations 11/7:
0 · Reply
LabPsycho
LabPsycho Nov. 5 at 5:42 PM
$FHTX Smarca2 as their lead...hmmm......look at PRLD and their smarca2 that they just seemingly tossed yesterday...
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 5 at 12:21 PM
$FHTX Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 4 at 2:26 PM
$FHTX fyi... prelude deprioritized their smarca2 program. this may have read through to foghorn's program. i think there other preclinical programs seem interesting and assume the lilly partnership could be maintained, if they also decide to deprioritize their smarca2 and pivot to another program. with that said, if they also announce a deprioritization, expect the stock price to drop. could be a good time to buy, at that time. wait for q3 er. “Having actively pursued the clinical development of our SMARCA2 selective degraders, we determined that complex biology and aggressiveness of disease in patients with SMARCA4 deletions will likely require early intervention and combination strategies to make a meaningful impact for patients." Prelude CEO
1 · Reply
LabPsycho
LabPsycho Nov. 4 at 2:23 PM
$FHTX @Baerchen 'partner with any Chinese or PD-L1 company....get any results you want [if the price is right!) Lol
0 · Reply
PaulLaurent
PaulLaurent Nov. 1 at 7:34 PM
🧭 Weekly Swing Recap $FHTX – Exceeded the target zone by $0.22. Clean execution; trims into strength worked. $IPHA – Target zone hit, but you had to be fast. Always place sells in the target zone—don’t wait for a unicorn (500%+). $NRGV – +14% from the entry; target not reached but still a profitable push. $NLSP$NCEL – +70% from the entry. Merger volatility knocked it after—lock gains when you have them. $ZENA – Never reached the entry zone—no entry. Tone: Discipline wins. Pre-set brackets, favor VWAP/pivot reclaims, scale out into strength, and protect gains if momentum cools.
3 · Reply
outlawinvestor1
outlawinvestor1 Oct. 28 at 4:35 PM
$FHTX great time to come into foghorn. tpd landscape is growing! only a matter of time before lilly buys this one. $GLUE $CCCC $ARVN $PRLD
0 · Reply
NotBornYesterday
NotBornYesterday Oct. 17 at 5:09 PM
$FHTX maybe…just maybe.
0 · Reply
stick_to_stocks
stick_to_stocks Oct. 7 at 8:58 PM
$FHTX added a bit
0 · Reply
topstockalerts
topstockalerts Oct. 2 at 8:48 PM
After Hours Top Gainers PT2 $STFS $ASTC $FEBO $FHTX $KLTO
0 · Reply
MargaretMeadors291
MargaretMeadors291 Sep. 21 at 1:36 PM
$FHTX Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative.
0 · Reply
enriqueorozco
enriqueorozco Sep. 18 at 2:42 PM
$FHTX NXXT simple math for retailers pay less per dollar of sales as growth reaccelerates. That’s how asymmetric bets get born.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 9 at 12:32 PM
$FHTX Excellent article that nails exactly where FHTX stands right now. So if you want to update your FHTX knowledge or get acquainted with FHTX, this is a must read. https://beyondspx.com/quote/FHTX/analysis/foghorn-therapeutics-unlocking-chromatin-control-with-a-deep-pipeline-and-strategic-partnership-nasdaq-fhtx
0 · Reply
ESGIntegration
ESGIntegration Aug. 27 at 5:07 AM
$FHTX volatile swings, risk management key here.
0 · Reply
Tacto
Tacto Aug. 20 at 9:12 AM
$FHTX One of the very few biotechs that's not overbought at the moment, not to mention that Foghorn only recently emerged from oversold territory. Could be a candidate for a fat swing. Let's see if a good entry point is in the cards today..
0 · Reply
Baerchen
Baerchen Aug. 12 at 1:29 AM
$FHTX When watching their latest presentation, focus was mostly on combination with in-house Olomorasib from LLY itself - LLY bought Loxo Oncology 2019 at 235$ - IPO was 13$ - Loxo was oncology specialty - since LLY has still interest in oncology and $FHTX is leading in this field - just the future knows. Big Pharma has to specialize in the future. LLY tends to go for Oncology/Diabetes/Obesity. $MRK tends to go for Immunology. $GILD goes for Infectious disease and somehow Liver disease. Vaccines are not that interesting anymore. KRAS has been an interesting topic. But $FHTX also seems to be more focusing in combining therapeutics, so they can partner up with any chinese Biotech or some PD1(L) - and get any results. Hot shit I think. Great management.
1 · Reply
Stmkr
Stmkr Aug. 7 at 7:19 AM
$FHTX Even timeline for updates a mystery.
0 · Reply
Stmkr
Stmkr Aug. 7 at 7:11 AM
$FHTX Lots of mystery pipeline... Strange that lead asset is an enzyme inhibitor (vs degrader)
1 · Reply
NotBornYesterday
NotBornYesterday Aug. 6 at 6:11 PM
$FHTX Chart setting up for potential repeat of 2H23. Another crack at buying well below net cash in the cards?
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 5 at 11:49 AM
$FHTX Foghorn Therapeutics Q2 EPS $(0.28) Beats $(0.33) Estimate, Sales $7.557M Beat $6.498M Estimate
0 · Reply
AnomalyDetective
AnomalyDetective Aug. 4 at 1:13 PM
$PRME $KYTX $FHTX $QS $SRFM breakout charts from prior selections in the free breakout blog: https://top.vmbreakouts.com/prme-47-picked-july-2nd/
0 · Reply